Replimune Group (NASDAQ:REPL) Trading Down 4.2% – Here’s What Happened

Replimune Group, Inc. (NASDAQ:REPL) fell 4.2% during mid-day trading on Monday . The company traded as low as $14.14 and last traded at $14.30. 134,294 shares traded hands during mid-day trading, a decline of 87% from the average session volume of 1,050,196 shares. The stock had previously closed at $14.93.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $17.00 target price on shares of Replimune Group in a report on Friday, November 22nd. JPMorgan Chase & Co. raised their target price on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, September 24th. Roth Mkm started coverage on shares of Replimune Group in a research report on Tuesday, August 27th. They set a “buy” rating and a $17.00 price target for the company. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. Finally, BMO Capital Markets upped their target price on shares of Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a research report on Friday, November 22nd. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $17.00.

Replimune Group Price Performance

The business has a 50-day simple moving average of $11.71 and a two-hundred day simple moving average of $9.86. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $961.26 million, a price-to-earnings ratio of -4.71 and a beta of 1.19.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.07. As a group, research analysts predict that Replimune Group, Inc. will post -2.99 earnings per share for the current fiscal year.

Insider Activity at Replimune Group

In other news, insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction on Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the transaction, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. The trade was a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 8.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Replimune Group

Institutional investors have recently bought and sold shares of the business. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Replimune Group during the first quarter worth approximately $1,088,000. Price T Rowe Associates Inc. MD increased its stake in shares of Replimune Group by 12.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock worth $53,505,000 after acquiring an additional 699,679 shares during the last quarter. LMR Partners LLP raised its holdings in shares of Replimune Group by 145.8% during the third quarter. LMR Partners LLP now owns 82,479 shares of the company’s stock worth $904,000 after acquiring an additional 48,920 shares in the last quarter. Millennium Management LLC grew its stake in Replimune Group by 575.1% in the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after purchasing an additional 2,656,173 shares in the last quarter. Finally, Cubist Systematic Strategies LLC increased its position in Replimune Group by 282.2% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company’s stock worth $650,000 after purchasing an additional 53,313 shares during the last quarter. 92.53% of the stock is currently owned by institutional investors and hedge funds.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.